-
公开(公告)号:US20200071353A1
公开(公告)日:2020-03-05
申请号:US16682855
申请日:2019-11-13
Applicant: GE HEALTHCARE BIOPROCESS R&D AB
Inventor: Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
IPC: C07K1/22 , C07K16/00 , C07K14/31 , B01J20/28 , B01J20/24 , B01D15/38 , C07K17/10 , B01J20/286 , B01J20/32 , C07K16/06
Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.
-
公开(公告)号:US20200239517A1
公开(公告)日:2020-07-30
申请号:US16095721
申请日:2017-05-10
Applicant: GE HEALTHCARE BIOPROCESS R&D AB
Inventor: Annika Forss , Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
Abstract: The present invention concerns a method of storing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support. The method comprises the steps of: a) providing a storage liquid comprising at least 50% by volume of an aqueous alkali metal hydroxide solution; b) permeating the separation matrix with the storage liquid; and c) storing the storage liquid-permeated separation matrix for a storage time of at least days. The alkali-stabilized Protein A domains comprise mutants of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by, or having at least 80% such as at least 90%, 95% or 98% identity to, SEQ ID NO 51 or SEQ ID NO 52, wherein the amino acid residues at positions 13 and 44 of SEQ ID NO 51 or 52 are asparagines and wherein at least the asparagine residue at position 3 of SEQ ID NO 51 or 52 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
-
公开(公告)号:US20200299326A1
公开(公告)日:2020-09-24
申请号:US16893574
申请日:2020-06-05
Applicant: GE HEALTHCARE BIOPROCESS R&D AB
Inventor: Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
IPC: C07K1/22 , C07K16/00 , C07K14/31 , B01J20/28 , B01J20/24 , B01D15/38 , C07K17/10 , B01J20/286 , B01J20/32 , C07K16/06
Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.
-
公开(公告)号:US10711035B2
公开(公告)日:2020-07-14
申请号:US16682855
申请日:2019-11-13
Applicant: GE HEALTHCARE BIOPROCESS R&D AB
Inventor: Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
IPC: A23J1/00 , C07K1/22 , C07K16/00 , C07K14/31 , B01J20/28 , B01J20/24 , B01J20/32 , B01D15/38 , C07K17/10 , B01J20/286 , C07K16/06
Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.
-
公开(公告)号:US10513537B2
公开(公告)日:2019-12-24
申请号:US16096952
申请日:2017-05-10
Applicant: GE HEALTHCARE BIOPROCESS R&D AB
Inventor: Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
IPC: A23J1/00 , C07K1/22 , C07K16/00 , C07K14/31 , B01J20/28 , B01J20/24 , B01D15/38 , C07K16/06 , C07K17/10
Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.
-
公开(公告)号:US20190144496A1
公开(公告)日:2019-05-16
申请号:US16096869
申请日:2017-05-10
Applicant: GE HEALTHCARE BIOPROCESS R&D AB
Inventor: Gustav José Rodrigo , Tomas Bjorkman , Mats Ander
IPC: C07K1/22 , C07K17/10 , B01J20/285 , B01J20/286 , C07K16/12 , B01J20/26 , C07K14/31 , C07K16/00
Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52, wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO: 4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
-
公开(公告)号:US20200299325A1
公开(公告)日:2020-09-24
申请号:US16095753
申请日:2017-05-10
Applicant: GE HEALTHCARE BIOPROCESS R&D AB
Inventor: Annika Forss , Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
IPC: C07K1/22 , C07K16/00 , C07K14/31 , B01J20/32 , B01J20/26 , B01J20/285 , B01J20/286 , C07K16/12 , C07K17/10
Abstract: The present invention concerns a method of cleaning and/or sanitizing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support. The method comprises the steps of: a) optionally purifying a mixture comprising a first immunoglobulin using the separation matrix; b) providing a cleaning liquid comprising at least 50% by volume of an aqueous alkali metal hydroxide solution; and c) cleaning and/or sanitizing the separation matrix by contacting the cleaning liquid with the separation matrix for a predetermined contact time. The alkali-stabilized Protein A domains comprise mutants of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO 51 or SEQ ID NO 52, wherein the amino acid residues at positions 13 and 44 of SEQ ID NO 51 or 52 are asparagines and wherein at least the asparagine residue at position 3 of SEQ ID NO 51 or 52 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
-
公开(公告)号:US20190119318A1
公开(公告)日:2019-04-25
申请号:US16096952
申请日:2017-05-10
Applicant: GE HEALTHCARE BIOPROCESS R&D AB
Inventor: Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.
-
-
-
-
-
-
-